Celgene’s Pomalyst Secures Breakthrough Designation
by Celgene’s Pomalyst (pomalidomide) has been designated a breakthrough therapy for HIV-positive and HIV-negative Kaposi Sarcoma Clinical Trial by the US Food and Drug Administration (FDA). …
Article Mania – Bloggers Unite India
Your Place to post Quality Articles.
Celgene’s Pomalyst (pomalidomide) has been designated a breakthrough therapy for HIV-positive and HIV-negative Kaposi Sarcoma Clinical Trial by the US Food and Drug Administration (FDA). …